DOSSIER DU CNHIM N°3 – 2015

Zone de Texte:                                      DOSSIER DU CNHIM N°3 – 2015

 

SOMMAIRE

 

Cancer de la prostate : traitements médicamenteux du cancer résistant à la castration

Laura Kramer, Olivier Huillard, Corinne Guérin et la participation du comité de rédaction

 

 

Editorial                        Nadine Houédé                                      3

En bref                          Marie-Caroline Husson                                                                              4

 

1.         Introduction                                                                                                                   4

2.         La prostate                                                                                                                     5

2.1        Anatomie                                                                                                                          6

2.2        Physiologie                                                                                                                       7

3.         Cancer de la prostate                                                                                                     9

3.1        Epidémiologie                                                                                                                   9

3.2        Facteurs de risque                                                                                                           10

3.3        Clinique                                                                                                                          10

3.4        Classifications et score                                                                                                     11

3.5        Physiopathologie                                                                                                              14

3.6        Dépistage et diagnostic                                                                                                    16

4.         Traitements du cancer de la prostate                                                                          17

4.1        Stratégies de décision : recommandations de l’AFU et de la HAS                                           17

4.2        Traitements du cancer de la prostate localisé                                                                      18

5.         Traitements médicamenteux du cancer de la prostate résistant à la castration : nouvelles thérapeutiques                                                                                                                       21

5.1        Résistance à la castration                                                                                                 21

5.2        Traitement du cancer métastatique : chimiothérapie cytotoxique                                          22

            par voie intraveineuse

5.3        Nouvelles thérapeutiques depuis 2011                                                                               22

5.4        Perspectives en immunotherapie : le sipuleucel-T                                                                39

6.         Traitement de l’atteinte osseuse                                                                                 43

6.1        Acide zolédronique                                                                                                           43

6.2        Dénosumab                                                                                                                    44

7.         Stratégie thérapeutique dans le cancer de la prostate résistant à la castration          48

7.1        Première ligne de traitement chez les malades métastatiques chimio-naïfs                             48

7.2        Deuxième ligne de traitement chez les malades métastatiques                                             49

7.3        Lignes de traitement restant à préciser chez les malades métastatiques                                50

7.4        Traitement de l’atteinte osseuse                                                                                        50

8.         Médicaments en essais cliniques de phase III                                                            51

8.1        DCVAC/PCa                                                                                                                     51

8.2        Ipilimumab                                                                                                                     52

8.3        Zibotentan (essai ENTHUSE)                                                                                             52

8.4        ODM 201 (essai ARAMIS)                                                                                                 52

8.5        ARN 509 - JnJ 56021927                                                                                                  52

8.6        Cabozantinib                                                                                                                   52

8.7        Orteronel (TAK-700)                                                                                                        52

8.8        Galétérone                                                                                                                      52

9.         Conclusion                                                                                                                    52

Glossaire                                                                                                                                 53

Acronymes et abréviations                                                                                                     53

Références bibliographiques                                                                                                  54

 

Fiche Erreur médicamenteuse                                                                                                      57

Erreur d’anticoagulation

Morgane Guilladin, Xavier Bohnand et la participation du comité de rédaction

 

Résumés des derniers numéros parus                                                                                                61

Au sommaire de Dossier du CNHIM                                                                                                   62

Bulletin d’abonnement 2015                                                                                                                                                                                                                                                            63

96, rue Didot-CS91425

75993 PARIS CEDEX 14

Tél : 01 56 53 51 05 - Fax : 01 57 05 96 03 - Email : secretariat@theriaque.org

Centre National Hospitalier d’Information sur le Médicament

Président du  CNHIM:

Xavier DODE

 

Rédactrice en chef du site:

Marie-Caroline HUSSON

 

Accueil

Echos du CNHIM

Parutions

Missions

Statuts

Composition

Partenaires

Point-rencontres

Adresses Utiles

Offres d'emploi

Annuaire

 

Information Adhérents

Nous contacter

Site compatible

Internet explorer 6 et +

Opera 9 et +